PK Study of CHF 5993 (Trimbow) pMDI vs DPI in Healthy Volunteers

Phase 1, randomised, open-label trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Area Under the Curve (AUC0-t) for Systemic Exposure at 72 hours, Area Under the Curve (AUC) for Lung Exposure at 72 hours and 2 more. Started Apr 2016; status: completed.